Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European Perspective
Heinz Ludwig(Wilhelminen Hospital), Antonio Palumbo(Azienda Ospedaliero Universitaria San Giovanni Battista), Pieter Sonneveld(Erasmus MC Cancer Institute), Hermann Einsele(Universitätsklinikum Würzburg), Jesús F. San Miguel(Clinica Universidad de Navarra), Thierry Façon(Université de Lille), Hila Magen‐Nativ(Rabin Medical Center), Torben Plesner(University of Southern Denmark), Joan Bladé(Hospital Clínic de Barcelona), Meletios Α. Dimopoulos(Korea University), Pia Sondergeld(Faringdon Day Hospital), U Hess(Université Paris Cité), Hareth Nahi(Karolinska University Hospital), Л. П. Менделеева(National Research Center for Hematology Russian Academy of Medical Sciences), Hartmut Goldschmidt(Heidelberg University), Vernon Louw(University of Cape Town), Michèle Cavo(Unknown), Meral Beksaç(Liv Hospital), Michel Delforge(KU Leuven), Fernando Leal da Costa(University of Alabama at Birmingham), Johannes Drach(Vienna General Hospital), Jean‐Luc Harousseau(Hospital de Santa Maria), Miklós Udvardy(University of Debrecen), Jamie Cavenagh(St Bartholomew's Hospital), Martin Kropff(University Hospital Münster)
Cited by 33
Related Papers
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Hematological findings and complications of <scp>COVID</scp>‐19
|American Journal of Hematology|2020|1.7k
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
|British Journal of Haematology|1998|1.5k